Larry Ellison, co-founder of Oracle Corporation, has an estimated net worth of approximately $200 billion, currently placing him among the third richest person in the world, according to Forbes.

Billionaire Larry Ellison’s backing of Stargate could help grease the wheels for the embattled merger between Paramount Global and Skydance Media, sources told The Post.

On Donald Trump's first full day in office for his second presidential term, he gathered Oracle founder Larry Ellison, OpenAI CEO Sam Altman and Softbank chief Masayoshi Son at the Roosevelt Room in the White House to unveil a $500 billion artificial intelligence project named after a 1994 Roland Emmerich sci-fi film about intergalactic portals.

He previously floated a joint venture, saying that the US should be entitled to half of the app.

As 2024 was drawing to a close, OpenAI CEO Sam Altman faced two major problems. He wasn’t getting enough server capacity from Microsoft, his company’s biggest backer, to stay ahead of rivals developing artificial intelligence.

Robby Soave and Niall Stanage weigh in on debate of using A.I. to develop mRNA vaccines to target cancer. #AI #mrnavaccines

President Donald Trump had recently expressed his support in SpaceX and Tesla CEO Elon Musk or Oracle CEO Larry Ellison purchasing TikTok.

Potential TikTok buyers are lining up as President Trump and the Chinese government show heightened interest in striking a deal to sell the popular video-sharing platform in the face of a U.S.

YouTuber MrBeast, X owner Elon Musk and Oracle Chairman Larry Ellison are names that have floated around in the past week.

Larry Ellison unveiled plans for an AI-driven cancer vaccine system that could deliver personalized treatments within 48 hours.

As TikTok faces a potential ban, various bidders, including Elon Musk and Larry Ellison, are key contenders to buy the platform. Meanwhile, Netflix remains a possible option among streaming giants, though the company has not historically pursued major acquisitions.

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to represent a sustainable long-term revenue generator.